Italian-led Ivermectin Meta-Analysis: Is it Time to Consider the Generic Low Cost Option to Help Treat COVID-19?

Italian-led Ivermectin Meta-Analysis Is it Time to Consider the Generic Low Cost Option to Help Treat COVID-19

A group of six critical care physicians and researchers, four of who are affiliated with IRCCS San Raffaele Scientific Institute in Milan, Italy, recently conducted a meta-analysis looking into ivermectin and along the way asking a highly uncomfortable question as to whether suspect claims about safety for commonly available drugs in fact are driven by a deep-seated, intensive fear of failure among the scientific and medical community. After all, tens of billions have been invested into a particular approach and anything that gets in the way could be deemed recognition of failure. In probing the ivermectin situation, the group, including four Italians, a Russian and Spanish doctors and researcher identified over 45 clinical trials ongoing involving ivermectin investigations. In performing yet another ivermectin meta-analysis covering a total of 1323 patients randomized across seven randomized controlled trials conducted in six countries, the group identified that in fact ivermectin treatment led to a statistically significant lower mortality rate when compared to placebo. The authors argue that while in fact “ironclad evidence” represents a fundamental underpinning of modern medicine, in emergency situations the use of an economical medication with a well-known safety profile, including absence of major side effects within dosage ranges, could be considered in fact quite rational. Despite the “urge” to demand large high quality randomized controlled trials, the authors declare that the existing ivermectin studies “point in the same direction” and this simply cannot be ignored. After all, the vaccines are still experimental, meaning they are authorized under emergency use authorization exactly due to conditions associated with pandemic times. Perhaps the authors imply, the same logic could be applied to ivermectin.

Studies

The authors shared a few of the studies, including the Bangladesh study led by Ahmed S where treating mild cases of SARS-CoV-2, the study used a dose of ivermectin of 12 mg for 5 days. The results were published in the International Journal of Infectious Diseases.

They also covered the Egyptian study led by Elgazzar A et al covering mild to severe COVID-19, using a dose of 400 mcg/kg (max 24 mg) for 4 days—the results are still in preprint. Yet another study led by Hashim HA in Iraq treated mild to severe cases with 200 mcg/kg for 2 to 3 days and available via the preprint server. Other studies included Niaee, MS et al from Iran, Okumus in Turkey, Ravikirti in India and another study out of Bangladesh authored by Mahmud R. 

Critique

Much of the scientific world hasn’t placed much emphasis on ivermectin studies unless they are peer reviewed and authored in respectable medical and scientific journals. While a few groups in the UK and USA have performed similar meta analysis, including the doctors from the Front Line Critical Care COVID-19 Alliance (FLCCC)Dr. Andrew Hill and Dr. Tess Lawrie, as well as an anonymous group that manages a running tally called @CovidAnalysis, common retorts are that these studies aren’t big enough, there is too much variance in design, dosage, etc.   

All apex research bodies such as the National Institutes of Health (NIH) select just a few of the ivermectin studies for review, but not all of them. The mainstream media only reports when news is neutral, such as the case of a recent Cali Colombia study that revealed at least in that case the drug didn’t have a statistical impact. See the link for the National Institutes of Health (NIH) COVID-19 Treatment Guidelines for Ivermectin.

About IRCCS San Raffaele Scientific Institute

Four of the six authors are affiliated with IRCCS Ospedale San Raffaele, a university hospital and scientific institute established in 1971 offering specialized care for the most complex health conditions, as well as conduct cutting-edge translational research. This academic medical center takes care of 50,000 inpatients per year, 1,500,000 outpatients and handles 70,000 emergencies a year as well as 30,000 annual surgical interventions. Of course, the study results are not necessarily the opinion of the institution.

The Authors

Pasquale Nardelli, Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan Italy

Alberto Zangrillo, Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan Italy and Vita-Salute San Raffaele University, Milan, Italy

Gabriele Sanchini, Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan Italy

Giovanni Landoni, Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan Italy and Vita-Salute San Raffaele University, Milan, Italy

Andrey G Yavorovskiy, IM Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Soledad Romero Garcia, Department of Anaesthesia and Critical Care, Consorcio Hospital General Universitario de Valencia, Valencia, Spain

Call to Action: Physicians and health care professionals should be looking around the world at what different medical professionals, societies and institutes are doing in terms of COVID-19 research. Knowledge is power.

Responses

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  1. Dr. Pierre Kory had GREAT NEWS yesterday! The FLCCC’s own meta analysis will be published in The American Journal of Therapeutics in May 2021!! Finally, a journal had the balls and integrity to publish this great document! Congratulations to all of us who have pushed and pushed and pushed to get this life saving information out to everyone we know.

  2. SSDD, and this will go nowhere just like the rest of them. Thanks docs, but no one is listening. I’ve been reading these stories at TSN for months. The entire medical community across the entire world are a bunch of button pushing cowards. Only a very few of them are brave enough to think for themselves even for a minute.

    1. Have faith! I think things are slowly turning around. I see some movement: just a day ago FLCCC’s own paper was finally accepted by a major journal, and one of the main UK tv channels had a full feature-length, totally objective and positive documentary about Ivermectin. I see cracks in the facade of the coverup, more and more power centers are slowly joining in. I predict that one major developed country will improve IVM for COVID within a month.